Cancer News and Research

Latest Cancer News and Research

North Shore-LIJ implements new program to ensure safe radiation therapy

Radiation oncologists took a blow in a series of front-page newspaper stories published last year on injuries that occurred nationwide in the delivery of radiation treatment. Radiation oncologists at North Shore-LIJ Health System responded to the public charge with a series of steps that will ensure that patients are protected at all points in the treatment process.

20 May 2011

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

A primary reason that head and neck cancer treatments fail is the tumor cells become resistant to chemotherapy drugs. Now, researchers at the University of Michigan Comprehensive Cancer Center have found that a compound derived from the Indian spice curcumin can help cells overcome that resistance.

20 May 2011

International team identifies key protein in development of drug-resistant leukemia

Now an international team led by researchers at the University of California, San Francisco and joined by scientists of the Freiburg excellence cluster BIOSS - Centre for Biological Signalling Studies, has identified a protein called BCL6 which plays a key role in the development of drug-resistance in leukemia.

20 May 2011

RTOG reports on largest trial for newly diagnosed glioblastoma

RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.

20 May 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced results from a Phase 2b trial evaluating Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic breast cancer previously treated with a bevacizumab-containing regimen, which showed that Nexavar was associated with statistically significant improvements in progression-free survival and time-to-progression.

20 May 2011

GIS discovery could help generate stem cells more efficiently for biomedical applications

A team of scientists from Genome Institute of Singapore (GIS) of the Agency for Science, Technology and Research (A*STAR) have shown how proteins involved in controlling genes work together to carry out their functions in stem cells and demonstrated for the very first time, how they can change interaction partners to make other types of cells.

20 May 2011

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments.

20 May 2011

Study: Costs get in way of cancer patients refilling their prescriptions

About 10 percent of cancer patients aren't taking the oral medicines they need either because of the cost or they feel they are already taking too many other drugs, according to a study released by health-care consulting company Avalere Health late Wednesday.

20 May 2011

HealthGrades identifies major flaws in hospital ratings study

The findings of a journal article published in the May issue of the Archives of Surgery are fundamentally flawed and could undermine patients ability to find high quality hospital care, according to HealthGrades. The article, Evaluating Popular Media and Internet-Based Hospital Quality Ratings for Cancer Surgery, compared outcomes for gastrointestinal cancer patients who underwent surgery at hospitals on HealthGrades' "America's 50 Best Hospitals" and US News and World Report's "America's Best Hospitals" lists.

20 May 2011

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Eli Lilly and Company announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.

20 May 2011

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

For my money, the most interesting thing about Mitt Romney's health-care speech last week wasn't his struggle to defend Romneycare and distance it from Obamacare, but the largely hostile reception of the speech from the right.

20 May 2011

$Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma$

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved a clinical benefit rate (CBR) (minimal response or greater) in the study population of 37 percent with a duration of response (DOR) of 8.3 months.

20 May 2011

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budgetary Healthcare Institution of Sverdlovsk Region - Sverdlovsk Regional Oncology Center in Ekaterinburg, Russia.

20 May 2011

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Enzon Pharmaceuticals, Inc. today announced that, in light of evolving standards of care for the treatment of metastatic colorectal cancer (mCRC), the Company will discontinue its PEG-SN38 (EZN-2208) clinical program in this disease, following conclusion of its Phase II study.

19 May 2011

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

Mitomics, world leader in the research and development of mitochondrial genome-based products, today announced it has entered into a non-exclusive licensing agreement with QDx Pathology Services to develop, market and process the QPredict™ Prostate Mitomic Test.

19 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, will be presenting data from the NeuVax Phase II adjuvant breast cancer clinical trial at the 2011 annual meeting of The American Society of Clinical Oncology in Chicago.

19 May 2011

Online program helps people to manage chronic pain

There is good news for the 76 million Americans who experience chronic pain including migraine, back pain, fibromyalgia and arthritis. A new study reveals that an online, self-paced chronic pain management program reduces the physical and psychological burdens of this debilitating condition.

19 May 2011

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.

19 May 2011

Cancer News and Research

Latest Cancer News and Research

North Shore-LIJ implements new program to ensure safe radiation therapy

Curcumin compound can help head and neck cancer cells overcome resistance to chemotherapy drugs

International team identifies key protein in development of drug-resistant leukemia

RTOG reports on largest trial for newly diagnosed glioblastoma

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

GIS discovery could help generate stem cells more efficiently for biomedical applications

VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

Study: Costs get in way of cancer patients refilling their prescriptions

HealthGrades identifies major flaws in hospital ratings study

Lilly's cixutumumab Phase II study results in five subtypes of sarcoma to be presented at 47th ASCO

Longer looks: Tough health care questions for GOP presidential contenders; Robotics help spike use of prostate treatment

Positive results from Onyx's carfilzomib Phase 2b 003-A1 study in relapsed and refractory multiple myeloma

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

Enzon to discontinue PEG-SN38 clinical program in metastatic colorectal cancer

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Mitomics enters licensing agreement with QDx Pathology Services for QPredict Prostate Mitomic Test

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

RXi to present updated NeuVax Phase II trial data in breast cancer at ASCO 2011

Online program helps people to manage chronic pain

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in